Retraction

Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer

Paper Information

Record ID:

59331

Author(s):

Xiaolei Wang
Yuxia Huang
Zhen Yang
Yang Yang
Fenfen Wei
Min Yan
Fanfan Li

Journal:

Computational and Mathematical Methods in Medicine ( Hindawi )

Publication Date:

September 17, 2022

Retraction Date:

December 13, 2023 (1.9 year years ago)

Subjects:

Broad Categories:
Medicine

Specific Fields:
Medicine - Obstetrics/Gynecology Medicine - Oncology Medicine - Pharmacology

Institutions:

Country:

🇨🇳 China

Article Type:

Research Article

Publisher:

Hindawi

Open Access:

Yes

DOI:

10.1155/2022/7864114

PubMed ID:

36164613

Retraction PubMed ID:

38124917

Retraction Details

Retraction Reasons:

Nature of Retraction:

Retraction

Retraction Notice:

10.1155/2023/9868302

Citations (3)

3

Total Citations

1

Post-Retraction
(33.3%)

1

Pre-Retraction

0

Same Day

Post-Retraction Citation Analysis

0 Within 30 days

1 Within 1 year

0 After 2+ years

110 Days since retraction (latest)

Heavy Metals Removal Using Carbon Based Nanocomposites

Unknown Authors

Unknown Journal

Published: Unknown

Comparison of the prognostic effect of pyrotinib plus trastuzumab and chemotherapy different lines therapy in HER2-positive advanced breast cancer

Yangqingqing Zhou, Hui Wang, Jiao Yang et al. (10 authors)

Journal of Chemotherapy

Published: Apr 2024

110 days after retraction

Retracted: Efficacy and Risk Factors of Pyrrotinib in Second‐ and Third‐Line Treatments for HER2‐Positive Advanced Breast Cancer

Computational and Mathematical Methods in Medicine

Computational and Mathematical Methods in Medicine Open Access

Published: Jan 2023

346 days before retraction

Quick Stats

Total Citations: 4

Years Since Retraction: 1.9 year

Open Access: Yes

Last Checked: Jul 24, 2025

Actions

More from this journal Similar subjects View Original Paper View Retraction Notice